Tests lymph node removal near the liver in ovarian cancer
Tests removing lymph nodes near the liver in adults with advanced or returning ovarian cancer.
Plain-language title generated from the registry record
Registry title: Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 75 with advanced ovarian, fallopian tube or primary peritoneal cancer, newly diagnosed or relapsed, who may have hepato-celiac lymph node spread and whose tumour can be fully removed by surgery.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer, or relapse that responds to platinum drugs. Lymph nodes near the liver and celiac area show cancer spread on imaging before surgery and are enlarged on touch during surgery. Surgeons judge that all visible tumour can be removed.
- Earlier treatment
- For newly diagnosed cancer, 1 to 3 rounds of chemotherapy before surgery are allowed. For relapse, no more than 4 earlier lines of therapy, and at least 6 months without platinum drugs.
Main reasons for not taking part
- Non-epithelial cancer, low-grade cancer or mucinous ovarian cancer
- Cancer that cannot be completely removed by surgery, or spread to lungs, liver tissue, brain or bone
- Cancer that grew after chemotherapy given before surgery
- Another cancer within 5 years, except carcinoma in situ or breast cancer without signs of relapse
- Other medical conditions that make surgery or chemotherapy unsafe
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05236686, who can take part
Where in China
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaContact: Libing XiangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Gynecologic Oncology Group
- Trial code
- NCT05236686
- Record updated
- 19 November 2025
- Original description
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.Read full original descriptionShow less
A Prospective, Multi-center, Single-Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Hepato-celiac Lymphadenectomy in the Treatment of Advanced and Recurrent Ovarian Cancer
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
Inclusion: Age ≥18 years to ≤ 75 years; Pathologic confirmed stage III or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (EOC, PPC, FTC) or platinum sensitive, relapsed EOC, PPC or FTC (no more than 4 lines of therapy); Hepato-celiac lymph nodes metastases diagnosed by imaging before surgery and enlarged palpable lymph nodes by surgical findings; Assessed by the experienced surgeons, complete resection is feasible according to preoperative evaluation; 1 to 3 episodes of neoadjuvant chemotherapy is allowed in primary settings; Platinum sensitive relapse is defined as those with platinum-free interval of 6 months or more; ASA score of 1 to 2; ECOG performance status of 0 to 2; Adequate bone marrow, liver and renal function to receive chemotherapy and subsequently to undergo surgery:; White blood cells >3,000/µL, absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL,; Serum creatinine <1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL/min according to Cockcroft-Gault formula or to local lab measurement; Serum bilirubin <1.25 x UNL, AST(SGOT) and ALT(SGPT) <2.5 x UNL; Comply with the study protocol and follow-up; Written informed consent.
Exclusion: Infeasible complete resection according to preoperative evaluation; Carcinomatosis on small bowel mesentery or intestinal wall by surgical findings and infeasible optimal surgery by bowel resection or peritonectomy; Progression after neoadjuvant chemotherapy in primary settings; Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise the adherence to the protocol; Patients with non-epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma; Mucinous ovarian cancer; Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ or breast cancer (without any signs of relapse or activity); Other conditions, such as religious, psychological and other factors, that could interfere with provision of informed consent, compliance to study procedures, or follow-up; Low-grade carcinoma; Unresectable pulmonary and hepatic parenchymal metastases, multiple thoracic lymph nodes metastases, brain or bone metastases according to preoperative evaluation.